BioVie Inc (NASDAQ:BIVI) announced that a poster detailing how its drug candidate NE3107 regulated specific genes in a way significantly correlated with observed cognitive and biomarker improvements will be presented at the Alzheimer’s Associate’s International Conference being held in Amsterdam this weekend from July 16 to 20.
The news sent BioVie's stock higher, with it up 5.4% at US$4.68 at Monday's close
The company said the new data being presented shows how NE3107 could potentially change or affect the degree of methylation of specific genes correlated with various disease markers.
The poster presentation, titled Treatment Induced Epigenetic Modifications in MCI and Probable Alzheimer’s, will showcase how patients with clinical dementia saw significant reductions in their DNA methylation and, in turn, observed improvements in various cognitive measures after being treated with NE3107 for three months.
“We believe that NE3107 is the first pharmaceutical candidate to obtain statistically significant data from a clinical trial indicating a potential ability to reduce DNA methylation and showing correlations with biomarkers,” BioVie CEO Cuong Do said in a statement.
“The data from this trial suggest that NE3107 may have the potential to change the degree to which specific genes in our body are epigenetically regulated. The data also suggest that the change in gene expression associated with NE3107 treatment may have potential functional correlations to many factors measured in this clinical trial, including cognition, inflammation, and traditional Alzheimer’s biomarkers such as CSF pTau and pTau/Aβ42 ratio.”
The poster will be presented on Sunday, July 16, from 8.45am to 4.15pm. BioVie noted that, due to the conference’s rules around disclosing data before the event, it will provide additional information next week once the data has been presented.
BioVie is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. Its drug candidate NE3107 inhibits inflammatory activation of ERK and NFkB (eg NF signalling) leading to neuroinflammation and insulin resistance, but not their homeostatic functions such as insulin signalling and neuron growth and survival.
Contact the author at emily.jarvie@proactiveinvestors.com
Follow her on Twitter @emilyjjarvie